Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Agenus Inc. (AGEN) CEO Garo Armen on Q3 2021 Results - Earnings Call Transcript
02:13pm, Tuesday, 09'th Nov 2021
Agenus Inc. (AGEN) CEO Garo Armen on Q3 2021 Results - Earnings Call Transcript
Agenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting
08:30am, Thursday, 04'th Nov 2021
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines desig
5 Penny Stocks To Watch For November With Potential Biotech Catalysts
10:30am, Sunday, 31'st Oct 2021
Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Info
Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?
10:00am, Sunday, 24'th Oct 2021
Biotech stocks that fall hard on bad news can rebound in a flash.
Here's Why Agenus Stock Is Getting Hammered Today
12:22pm, Friday, 22'nd Oct 2021
The company's experimental anti-PD1 drug hit a wall.
Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
08:30am, Tuesday, 12'th Oct 2021
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
2 Stocks Set to Win From the Historic Malaria Vaccine Approval
05:52am, Tuesday, 12'th Oct 2021
But those wins probably won't be all that big.
Agenus to Present AGEN1181 Clinical Data at SITC
08:00am, Friday, 01'st Oct 2021
LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
MiNK Therapeutics: iNKT Cell Therapy Subsidiary Of Agenus Files For IPO
05:20pm, Monday, 20'th Sep 2021
MiNK Therapeutics: iNKT Cell Therapy Subsidiary Of Agenus Files For IPO
Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer
06:35am, Friday, 17'th Sep 2021
Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology ( ESMO21 ) Virtual Conference 2021. Related: Agenus Gains As Bal
Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
06:25pm, Thursday, 16'th Sep 2021
LEXINGTON, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines desi
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
07:30am, Friday, 10'th Sep 2021
Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines Development of saponin molecules designed to provide high-efficacy and long-lasting
Balstilimab Monotherapy Data Published in Gynecologic Oncology
09:00am, Thursday, 26'th Aug 2021
LEXINGTON, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains
02:42pm, Wednesday, 25'th Aug 2021
In Q42021 (likely at SITC), AGEN is anticipated to publish updated 1181/Bal Phase 2 clinical data in MSS-CRC that shows 1181/Bal significantly outperforms current FDA approved 3rd line standard-of-car
Agenus Multiple Value-Adding Events Ahead
03:54am, Wednesday, 18'th Aug 2021
Agenus Multiple Value-Adding Events Ahead
